Arbitration against Chugai commenced

10 August 2017

Japanese drug major Chugai Pharmaceutical (TYO: 4519) today announced that an arbitration against Chugai has been commenced by the UK’s Medical Research Council and LifeArc (formerly, Medical Research Council Technology).

Arbitration is a private and confidential dispute resolution procedure, however the parties have agreed to this disclosure. Sums are sought from Chugai, which is majority-owned by Swiss pharma giant Roche (ROG: SIX), for alleged breach of obligations under a collaboration agreement dated August 15, 1990 in connection with the development of the humanized anti-human interleukin (IL)-6 receptor monoclonal antibody, Actemra (tocilizumab), for the treatment of rheumatoid arthritis. It is claimed that Chugai is obliged to pay royalties to the Claimants pursuant to the collaboration agreement.

Chugai says it considers that the claims are without merit and will vigorously defend itself in the arbitration. At this moment, no change is expected to the financial prospects of Chugai.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK